onr:"swepub:oai:lup.lub.lu.se:5928a87a-a070-4db4-bcc3-1fc6e85d3602"
Search: onr:"swepub:oai:lup.lub.lu.se:5928a87a-a070-4db4-bcc3-1fc6e85d3602" > Second malignancies...
- 1 of 1
- Previous record
- Next record
- To hitlist
- Maclachlan, KyleeMemorial Sloan-Kettering Cancer Center (author)
Second malignancies in multiple myeloma; emerging patterns and future directions
- Article/chapterEnglish2020
Publisher, publication year, extent ...
- Elsevier BV,2020
Numbers
- LIBRIS-ID:oai:lup.lub.lu.se:5928a87a-a070-4db4-bcc3-1fc6e85d3602
- https://lup.lub.lu.se/record/5928a87a-a070-4db4-bcc3-1fc6e85d3602URI
- https://doi.org/10.1016/j.beha.2020.101144DOI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- The changing landscape of treatment options for multiple myeloma has led to a higher proportion of patients achieving deep, long-lasting responses to therapy. With the associated improvement in overall survival, the development of subsequent second malignancies has become of increased significance. The risk of second malignancy after multiple myeloma is affected by a combination of patient-, disease- and therapy-related risk factors. This review discusses recent data refining our knowledge of these contributing factors, including current treatment modalities which increase risk (i.e. high-dose melphalan with autologous stem cell transplant and lenalidomide maintenance therapy). We highlight emerging data towards individualized risk- and response-adapted treatment strategies and discuss key areas requiring future research.
Subject headings and genre
- MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Hematologi hsv//swe
- MEDICAL AND HEALTH SCIENCES Clinical Medicine Hematology hsv//eng
- Autologous
- Lenalidomide
- Melphalan
- Multiple myeloma
- Neoplasms
- Risk factors
- Second primary
- Transplantation
Added entries (persons, corporate bodies, meetings, titles ...)
- Diamond, BenjaminMemorial Sloan-Kettering Cancer Center (author)
- Maura, FrancescoMemorial Sloan-Kettering Cancer Center (author)
- Hillengass, JensRoswell Park Cancer Institute (author)
- Turesson, IngemarLund University,Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital(Swepub:lu)medf-itu (author)
- Landgren, C. OlaMemorial Sloan-Kettering Cancer Center (author)
- Kazandjian, DickranNational Cancer Institute, USA (author)
- Memorial Sloan-Kettering Cancer CenterRoswell Park Cancer Institute (creator_code:org_t)
Related titles
- In:Best Practice and Research: Clinical Haematology: Elsevier BV33:11521-6926
Internet link
Find in a library
- Best Practice and Research: Clinical Haematology (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Maclachlan, Kyle ...
- Diamond, Benjami ...
- Maura, Francesco
- Hillengass, Jens
- Turesson, Ingema ...
- Landgren, C. Ola
- show more...
- Kazandjian, Dick ...
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Hematology
- Articles in the publication
- Best Practice an ...
- By the university
- Lund University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
